Skip to main content
. 2011 Jun;3(3):133–149. doi: 10.1177/1759720X11407540

Figure 1.

Figure 1.

Summary of patients and clinical trials in the all-exposed safety population.

MTX, methotrexate; IR, inadequate responder; TCZ, tocilizumab; TNF, tumor necrosis factor; DMARD, disease-modifying antirheumatic drug.

* Includes patients in the control arm of study.

† All-exposed population = all patients who have received at least one dose of TCZ in the controlled phase or extension studies.

Source: van Vollenhoven et al. [2009b]. ACR Oral presentation no. 1955.